|  Sign up!  

scientia

Return to Course Listing

 

 

CME: The Newest in Non-Small Cell Lung Cancer (NSCLC): Emerging Therapies, Novel Approaches, Therapeutic Updates, and Barriers to Care and Incorporating Best Practice

 


Program Description / Statement of Need:

In this online CME self-learning program:

Lung cancer is the leading cause of cancer-related death in the United States with nearly 221,000 new cases diagnosed and 156,390 deaths annually. While surgery in eligible candidates and early detection provide the best chances for cure, there are many patients who must be treated by alternative modalities, including those with advanced disease.  Increasingly now, research is uncovering the role of biomarkers and genetic mutations in aiding not only the prognosis of NSCLC, but also its management.  They have given rise to targeted therapies that mechanistically alter cellular signaling pathways in a manner that suppresses angiogenesis and oncologic disease progression.

 

On the practical side, the literature also suggests that: there are or may be emerging or existing patterns of disparities in healthcare, treatment, and outcomes of patients with NSCLC on the basis of race, disability, and insurance coverage.  In particular, race- and ethnicity-based discrimination within the healthcare environment are associated with disparities in care; and that such discrimination is associated with both worse chronic health condition control and a higher incidence catastrophic health events.

 

This program has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment of NSCLC up to date and to enhance their competence in caring for patients with NSCLC.  This program also attempts to examine the role of disparities in care of patients with NSCLC and strategies to minimize or alleviate those disparities.

 

Agenda

 

Faculty introduction, disclosures

Introductory content, pathophysiology, and histopathology  

  • Epidemiology: statistics by severity
  • Lesion biopsy timing, adequacy of tissue sample volume, histopathology and subtypes
  • Pathogenesis and the role of the immune system
  • Updates in biomarkers, staging, and mutation statues

Updates in treatment in patients with NSCLC 

  • Clinical trials: what is new, and how should it impact practice?
  • Appropriate and approved molecular testing, biomarker analysis, and genetic mutations, and use thereof to guide treatment
  • Therapy sequencing
  • Clinical pearls: safety, tolerability, educating the patient (including managing treatment expectations), improving the provider-patient relationship, and those factors’ impact patient outcomes, including adherence to therapy
  • Emerging therapeutic options for NSCLC: what is on the horizon?
  • Patient case(s)

Summary, conclusions, and best practice recap


 

Target Audience:

 

Healthcare professionals specializing in: interventional radiology; nuclear medicine; oncology; palliative care; pathology; pulmonology; or those who otherwise commonly care for patients with NSCLC.



Program Objectives:

By the end of the session the participant will be able to:

    • Describe the impact of biomarker and mutation testing and their results for the management of patients with NSCLC and apply this knowledge to patient cases.
    • Describe the role and impact of the initial biopsy, including the relevance of its timing and factors affecting quality of results.
    • Distinguish between different NSCLC disease subtypes on the basis of histology, biomarker, and mutation status and use the information to optimize care in the setting of patient cases.
    • Discuss the ways that NSCLC has proved resistant to treatments in past and the mechanisms of action of targeted therapies, present and emerging
    • Determine how to incorporate the following components into a NSCLC treatment regimen in a manner that optimizes efficacy, safety, and tolerability: sequencing, dose reduction, and biomarker and mutation status testing


    Accreditation:

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

     

    Credit Designation: ScientiaCME designates this educational activity for a maximum of  1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

     

    Pharmacists

     

    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-16-004-H01-P.  ACPE Accreditation effective 5/10/2016, expires 5/10/2018.



    Release Date: May 09, 2016
    Expiration Date: May 09, 2018

    Faculty: Deepa Subramaniam MD MSc


    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

     

    Faculty Disclosure: Deepa Subramaniam, MD has received financial compensation from AstraZeneca (consultant)

     

    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.

     

    Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim

     

    Viewing Instructions

     

    PC

    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    MAC
    Mac OS 10.2.8
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh

     

    *Required to view Printable PDF Version

     

    Privacy Policy

     

    Instructions:


    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.



    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


    Download the Presentation (optional)


     

    View the online program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate



Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim

 


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.